Company
Zentalis
Unlocking a new targeted approach to cancer
Also known as Zentalis Pharmaceuticals, Inc., ZNTL
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- physicians and patients
- Legal name
- Zentalis Pharmaceuticals, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Zentalis is developing a differentiated oral therapy that targets WEE1 kinase, a key regulator of cell-cycle progression. WEE1 kinase inhibition is a novel approach that breaks down the safeguards that cancer cells use to survive.
Products
- Other
- azenosertib
- Web
- Azenosertib
Loading relationship preview